Welcome to our dedicated page for BETTERLIFE PHARMA news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on BETTERLIFE PHARMA stock.
BETTERLIFE PHARMA INC (BETRF) is a pharmaceutical company dedicated to developing innovative therapies for mental health disorders and neurological conditions. With a focus on research and development, the company is at the forefront of advancements in treatment options. BETRF's strong financial position and strategic partnerships enhance its ability to bring novel products to market.
BetterLife Pharma announced the successful completion of Phase 1 in its IN2COVID trial for inhaled interferon alpha-2b product, AP-003, aimed at treating COVID-19. Eighteen healthy subjects were enrolled, showing excellent safety and tolerability with no serious adverse events. Moving to Phase 2, the study's goal is to assess the effectiveness of AP-003 against COVID-19, especially with the emergence of variants like Omicron. The promising results from earlier studies underscore AP-003's potential as a broad-spectrum antiviral agent.
BetterLife Pharma announced the successful acquisition of behavioral animal pharmacology data for its lead compound, 2-bromo-LSD (TD-0148A), in collaboration with UC San Diego. This second-generation LSD derivative aims to treat mental disorders without psychedelic effects. The initial studies show that TD-0148A does not induce hallucinogenic responses in mice, unlike traditional LSD. BetterLife plans to advance TD-0148A towards clinical trials, focusing on treating conditions like depression and PTSD. The collaboration leverages the expertise of Dr. Halberstadt in psychedelic pharmacology.
BetterLife Pharma will participate in the Microdose Wonderland Miami Conference on November 8-9, 2021, focusing on psychedelic medicine. The event will feature industry leaders and discussions on topics such as the potential of psychedelic medicine and its implications for mental health treatments. BetterLife is developing two compounds, TD-0148A and TD-010, aimed at neuropsychiatric disorders. TD-0148A has a unique patent status that could facilitate its market entry, while TD-010 targets anxiety-related disorders. The global market for depression drugs is projected to reach nearly $25 billion by 2030.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced the successful acquisition of neurological receptor functional binding data for its lead compound, 2-bromo-LSD (TD-0148A). This second-generation LSD derivative aims to provide therapeutic benefits for neuropsychiatric disorders without psychoactive side effects. The receptor data indicates differential activity on key serotonin receptors, critical for conditions like depression and PTSD. BetterLife anticipates advancing TD-0148A toward US IND approval and clinical trials by H2 2022, supported by multiple patents.
BetterLife Pharma Inc. announced promising in vitro results for its recombinant human interferon alpha-2b (rhIFN⍺2b) against the Delta variant of SARS-CoV-2, achieving up to 97% protection in human cells. Further studies are ongoing to assess its effectiveness against other variants, including Gamma and Lambda. The company is conducting a Phase 1-2 trial in Chile, evaluating its inhaled therapy in early COVID-19 patients. CEO Ahmad Doroudian expressed optimism about overcoming therapeutic challenges posed by emerging variants.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has announced the successful acquisition of neurological receptor binding data for its lead compound, 2-bromo-LSD (TD-0148A). Conducted by Eurofins Discovery, the data suggests binding to key receptors linked to neuro-psychiatric disorders, indicating potential therapeutic applications. The company aims to advance TD-0148A towards IND status for clinical trials targeting conditions like depression and PTSD. Additionally, BetterLife welcomed David Melles as the new Investor Relations Manager to strengthen its investor engagement efforts.
BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has applied for patent protection for new compositions of 2-bromo-LSD, targeting cluster headaches, neuropathic pain, and mental health disorders like depression and PTSD. The second-generation LSD derivative, TD-0148A, is non-hallucinogenic and not subject to controlled substance regulations, facilitating its self-administration. The company is in advanced GMP manufacturing and preclinical IND-enabling studies, with plans to file an IND and commence Phase 1 and 2 trials in 2022.
BetterLife Pharma has initiated the IN2COVID trial in collaboration with Pontificia Universidad Católica de Chile, enrolling the first patient. This Phase 1-2 trial will evaluate AP-003, an inhaled interferon alpha-2b product, in COVID-19 patients. The trial includes a randomized placebo-controlled Phase 1 and a Phase 2 segment for patients diagnosed within five days. Dr. Ahmad Doroudian, BetterLife's CEO, expressed enthusiasm for the collaboration, while experts emphasized the need for effective treatments given emerging variants and breakthrough infections.
BetterLife Pharma has been invited to present at the Emerging Growth Conference on September 15, 2021. The company’s CEO, Dr. Ahmad Doroudian, will discuss the status of their neurological treatment programs, specifically focusing on compounds TD-0148A and TD-010. BetterLife’s presentation is scheduled for 11:15 AM Eastern Time.
Participants can engage with Dr. Doroudian live or watch a recorded version afterward. BetterLife is dedicated to treating neurological conditions, with a focus on depression and anxiety-related disorders.
BetterLife Pharma Inc. has partnered with Dr. John McCorvy at the Medical College of Wisconsin to conduct preclinical receptor binding studies for TD-0148A, a non-hallucinogenic LSD derivative aimed at treating cluster headaches and major depressive disorder. CEO Ahmad Doroudian highlighted the need for innovative therapies for psychiatric disorders. This partnership will explore TD-0148A's interaction with G protein coupled receptors to assist in its clinical development. BetterLife continues to focus on developing treatments for neurological conditions, with a market potential of nearly $25 billion for depression drugs by 2030.
FAQ
What is the current stock price of BETTERLIFE PHARMA (BETRF)?
What is the market cap of BETTERLIFE PHARMA (BETRF)?
What is the core focus of BETTERLIFE PHARMA INC?
What sets BETRF apart from other pharmaceutical companies?
How can I contact Investor Relations at BETRF?
Does BETRF have any recent achievements?
What is the goal of BETTERLIFE PHARMA INC?
How can I stay informed about BETRF's latest developments?
Is BETRF actively involved in research and development?
What are some of BETRF's strategic partnerships?
Where is BETTERLIFE PHARMA INC headquartered?
What is the vision of BETTERLIFE PHARMA INC?
